Professor Richard Haynes
Research groups
- 3C: A CAMPATH, Calcineurin inhibitor reduction and Chronic allograft nephropathy trial
- ASCEND: A Study of Cardiovascular Events iN Diabetes
- BEST-D: Biochemical Efficacy and Safety Trial of Vitamin D
- EASi-KIDNEY
- EMPA-KIDNEY: the study of heart and kidney protection with empagliflozin
- HPS2 -THRIVE: Treatment of HDL to Reduce the Incidence of Vascular Events
- Mexico City Prospective Study Estudio Prospectivo de la Ciudad de México
- Renal Studies Group
- SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
- SHARP: Study of Heart and Renal Protection
- Trials methodology
- UK HARP III
- Genetic determinants of chronic kidney disease progression
Richard Haynes
DM, MRCP
Professor of Renal Medicine and Clinical Trials
- Co-director Clinical Trial Service Unit & Epidemiological Studies Unit
- MSc in Global Health Science and Epidemiology module 8 lead: Clinical Trials and Meta-analysis
Richard Haynes is Professor of Renal Medicine and Clinical Trials. He is a practising honorary consultant nephrologist at the Oxford Kidney Unit and jointly leads the Renal Studies Group within CTSU.
He came to CTSU in 2006 during his clinical training to work on the THRIVE trial with Professor Jane Armitage and Professor Martin Landray. He has since worked on a number of cardiovascular trials, and helped establish and conduct several trials in nephrology including the 3C Study in kidney transplantation, UK HARP-III, EMPA-KIDNEY and EASi-KIDNEY.
He was the clinical trial unit lead for RECOVERY when it was set up in 2020 for which he was awarded an MBE in the 2021 New Year Honours. He continues to work in trials in outbreak situations including PLATINUM (mpox) and PARTNERS (filovirus disease), and is interested in applying streamlined trial methods to other areas of medicine.
He also teaches on the MSc in Global Health Science and Epidemiology and MSc in Clinical Trials, and through these courses and by demonstrating examples wants to make randomisation a normal part of clinical care in health systems worldwide.
Recent publications
-
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2025), Nephrol Dial Transplant, 40, 720 - 730
-
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group None. et al, (2025), N Engl J Med, 392, 777 - 787
-
The prevention and management of chronic kidney disease among patients with metabolic syndrome.
Zhu D. et al, (2025), Kidney Int
-
Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease.
Zhu D. et al, (2025), Nephrol Dial Transplant, 40, i70 - i79
-
Sotrovimab versus usual care in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)
Horby PW. et al, (2025)